by Clinical Neuropsychologist | Monday, October 21, 2024 | Dementia
Abstract On the 20th anniversary of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), this paper provides a comprehensive overview of the role of arterial spin labeling (ASL) magnetic resonance imaging (MRI) in understanding perfusion changes in the aging...
by Clinical Neuropsychologist | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining Alzheimer’s disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to...
by Clinical Neuropsychologist | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION Evaluating the generalizability of dementia risk scores, primarily developed in non-Latinx White (NLW) participants, and interactions with genetic risk factors in diverse populations is crucial for addressing health disparities. METHODS We...
by Clinical Neuropsychologist | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is a common disorder of the elderly that is both highly heritable and genetically heterogeneous. METHODS We investigated the association of AD with both common variants and aggregates of rare coding and non-coding...
by Clinical Neuropsychologist | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION Cerebrospinal fluid (CSF) α-synuclein (α-syn) seed amplification assay (SAA) is a sensitive and specific tool for detecting Lewy body co-pathology in Alzheimer’s disease. METHODS A total of 1637 cross-sectional and 407 longitudinal CSF...
by Clinical Neuropsychologist | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION This study assessed the association of plasma biomarkers of endothelial dysfunction with cognitive performance and decline. METHODS Data from 9414 individuals from eight Dutch cohorts were included (Ø age-range: 57–93 years). Plasma biomarkers...
